Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach

In phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old man with a previous history of left nephrectomy for a stage II clear cell renal carcinoma. Approximately 18 months later, recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Alpuim Costa, Diogo, Baptista de Almeida, Susana, Coelho Barata, Pedro, Quintela, António, Cabral, Pedro, Afonso, Ana, Maia Silva, João
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788070/
https://www.ncbi.nlm.nih.gov/pubmed/29387004
http://dx.doi.org/10.1159/000484402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788070/
https://www.ncbi.nlm.nih.gov/pubmed/29387004
http://dx.doi.org/10.1159/000484402

Ejemplares similares